Pro-Dex, Inc.
PDEX Healthcare Medical Instruments & Supplies
Pro-Dex, Inc.’s revenue for fiscal 2026 (year ended June 2026) was $77.5 million, up 16.5% from fiscal 2025. In the quarter to June 2026, revenue grew 16.7%, EPS grew 143.2%, free cash flow fell 79.0% and total debt rose 43.5%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.
Follow PDEX
Pro-Dex, Inc. (PDEX) EV/Sales
As of 16 October 2026, Pro-Dex, Inc. (PDEX) trades at a EV/Sales of 2.5×. Over the past ten years it has ranged from 0.4× (January 2016) to 4.4× (December 2020); the current reading is higher than 84% of that period. That is below the Medical Instruments & Supplies industry median of 2.9× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2026 | 2.5× | 13.74% |
| FY2025 | 2.2× | 81.38% |
| FY2024 | 1.2× | (23.96%) |
| FY2023 | 1.6× | (0.01%) |
| FY2022 | 1.6× | (50.81%) |
| FY2021 | 3.2× | 75.41% |
| FY2020 | 1.8× | (0.54%) |
| FY2019 | 1.8× | 97.50% |
| FY2018 | 0.9× | 2.70% |
| FY2017 | 0.9× | (15.89%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 2.5× | 15.58% |
| Mar 2026 | 2.2× | 24.87% |
| Dec 2025 | 1.7× | 11.52% |
| Sep 2025 | 1.5× | (29.33%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| ZJYL Jin Medical International Ltd. compare | n/m |
| NYXH Nyxoah SA compare | 0.7× |
| OSUR OraSure Technologies, Inc. compare | 0.8× |
| EMBC Embecta Corp. compare | 1.6× |
| PDEX Pro-Dex, Inc. | 2.5× |
| KRMD KORU Medical Systems, Inc. compare | 2.9× |
| SMTI Sanara MedTech Inc. compare | 2.9× |
| STXS Stereotaxis Inc. compare | 3.1× |
| UTMD Utah Medical Products, Inc. compare | 4.2× |
| Medical Instruments & Supplies industry median | 2.9× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)